Consider BREO ELLIPTA as your choice of ICS / LABA for your patients with moderateto-severe asthma 1
In the Salford Lung Study , a real-world effectiveness trial : 2
Consider BREO ELLIPTA as your choice of ICS / LABA for your patients with moderateto-severe asthma 1
In the Salford Lung Study , a real-world effectiveness trial : 2
Patients treated with BREO ELLIPTA achieved superior asthma control * versus usual care ( ICS or ICS / LABA ) at 24 weeks
OR 2.00 ( 95 % CI : 1.70-2.34 ) ( p < 0.0001 ) 2 * Patients with an ACT score of ≥20 or an increase from baseline of ≥3 points . ( Primary outcome ).
Scan the QR code to access BREO ELLIPTA resources , and order samples
The safety and tolerability profile of BREO ELLIPTA in asthma was similar to usual care^ ( reported SAEs : 13 % in both arms ) 3
^ICS or ICS / LABA
BREO ELLIPTA is indicated for the regular treatment of moderate-to-severe asthma in patients requiring medium to high dose inhaled corticosteroid ( ICS ) combined with long acting β2-agonist ( LABA ). 1
The recommended starting dose of BREO ELLIPTA is 100 / 25 mcg ( patients requiring a mid-dose ICS ) or 200 / 25 mcg ( patients requiring a higher dose ICS ) one inhalation once daily . 1
BREO ELLIPTA safety information : Very common : headache , nasopharyngitis . Common : URTI , bronchitis , influenza , oral candidiasis of mouth and throat , oropharyngeal pain , sinusitis , pharyngitis , rhinitis , cough , dysphonia , abdominal pain , arthralgia , back pain , pyrexia , muscle spasms . Fractures and pneumonia in patients with COPD . 1
Ask your patients to rinse their mouth after using BREO ELLIPTA . Inhaler not to scale
Scan QR code to see full BREO ELLIPTA Product Information Please review product information before prescribing . Product Information can be accessed at www . gsk . com . au / breo
PBS Information ( BREO ELLIPTA ): Authority Required ( STREAMLINED ): Asthma and Chronic Obstructive Pulmonary Disease . Criteria apply . Refer to PBS Schedule for full authority information .
Woodcock et al . 2017 study design : 12-month , prospective , open-label , pragmatic RCT evaluating the effectiveness and safety of BREO ELLIPTA ( 100 / 25 mcg or 200 / 25 mcg ) compared with usual care ( pre-existing regular maintenance therapy with ICS or ICS / LABA ). The trial was conducted in and around Salford and South Manchester , UK in symptomatic asthma patients ( n = 4,233 ) seen in general practice . The doses of all medications were permitted to be adjusted at the GP ’ s discretion . The primary endpoint was the percentage of patients in each treatment arm , who have either an ACT total score of ≥20 or an increase from baseline of ≥3 in ACT total score at week 24 , in the primary effectiveness analysis population . 2
ACT , Asthma Control Test ; CI , confidence interval ; ICS , inhaled corticosteroid ; LABA , long acting β2-agonist ; OR , odds ratio ; SAEs , serious adverse events ; URTI , upper respiratory tract infection . References : 1 . BREO ELLIPTA Product Information . 2 . Woodcock A et al . Lancet 2017:390 ( 10109 ): 2247 – 55 . 3 . Data on File .
For information on GSK products or to report an adverse event involving a GSK product , please contact GSK Medical Information on 1800 033 109 . GlaxoSmithKline Australia Pty Ltd ABN 47 100 162 481 , Melbourne , VIC . Trade marks are owned by or licensed to the GSK group of companies . © 2024 GSK group of companies or its licensor . PM-AU-FFV-JRNA-240002 . Date of approval : June 2024 .